Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis  by Vardakas, Konstantinos Z. et al.
International Journal of Infectious Diseases 16 (2012) e768–e773Review
Risk factors for development of Clostridium difﬁcile infection due to BI/NAP1/027
strain: a meta-analysis
Konstantinos Z. Vardakas a,b, Athanasios A. Konstantelias a,c, Giorgos Loizidis a,d, Petros I. Rafailidis a,b,
Matthew E. Falagas a,b,e,*
aAlfa Institute of Biomedical Sciences, 9 Neapoleos Street, 151 23 Marousi, Athens, Greece
bDepartment of Medicine, Henry Dunant Hospital, Athens, Greece
cDepartment of Surgery, Agia Soﬁa Children’s Hospital, Athens, Greece
dAthens University School of Medicine, Athens, Greece
e Tufts University School of Medicine, Boston, Massachusetts, USA
A R T I C L E I N F O
Article history:
Received 8 May 2012
Received in revised form 28 May 2012
Accepted 4 July 2012
Corresponding Editor: Andy Hoepelman,
Utrecht, the Netherlands
Keywords:
Clostridium difﬁcile
Infection
BI/NAP1/027
S U M M A R Y
Objective: To identify risk factors for the development of Clostridium difﬁcile infection (CDI) due to C.
difﬁcile BI/NAP1/027 strain.
Methods: PubMed and Scopus databases were searched for studies that sought to identify risk factors for
CDI due to the BI/NAP1/027 strain. The technique of meta-analysis was applied.
Results: Five studies compared CDI BI/NAP1/027 patients to CDI patients infected with non-BI/NAP1/027
strains, one compared CDI BI/NAP1/027 patients to non-CDI patients, and one provided data for both
comparisons. The meta-analysis showed that ﬂuoroquinolones were associated with a higher risk of CDI
due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (odds ratio (OR) 1.96, 95% conﬁdence
interval (95% CI) 1.37–2.80). A trend towards a lower risk for CDI due to BI/NAP1/027 was observed with
cephalosporins when compared to non-BI/NAP1/027 CDI (OR 0.70, 95% CI 0.46–1.07). Prior macrolides
were not associated with a higher risk for CDI BI/NAP1/027 when compared with non-BI/NAP1/027 CDI
controls (OR 0.88, 95% CI 0.44–1.78). Clindamycin administration was associated with a lower risk for
CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (OR 0.24, 95% CI 0.12–0.48). Age over
65 years was associated with an increased risk of CDI BI/NAP1/027 compared to non-BI/NAP1/027 CDI
(OR 1.77, 95% CI 1.31–2.38).
Conclusions: Fluoroquinolones and age over 65 years were associated with a higher risk of CDI due to the
BI/NAP1/027 strain. Clindamycin was associated with a lower risk of CDI due to BI/NAP1/027.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Clostridium difﬁcile is a signiﬁcant cause of nosocomial and post-
antibiotic diarrhea worldwide.1,2 Several strains, depending on
their ability to produce toxins, have been associated with more
severe disease.2 Among them, strain BI/NAP1/027 (REA group BI;
pulsed-ﬁeld gel electrophoresis type NAP1; PCR ribotype 027) has
attracted attention due to its propensity to cause multiple
outbreaks with an unexpected higher mortality.3–6 This new
strain was ﬁrst isolated in North America, but has since been
identiﬁed in Europe and Asia.
The risk factors for C. difﬁcile infection (CDI) have been well
described: use of antibiotics, hospitalization or nursing home
residency, aging, immunosuppression, inﬂammatory bowel dis-
ease, and recently proton pump inhibitors.1,2,7 However, due to its* Corresponding author. Tel.: +30 694 611 0000; fax: +30 210 683 9605.
E-mail address: m.falagas@aibs.gr (M.E. Falagas).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.07.010higher virulence, C. difﬁcile BI/NAP1/027 could be associated with
additional or different risk factors. The scope of this meta-analysis
was to identify the risk factors for the development of CDI due to C.
difﬁcile BI/NAP1/027 strain.
2. Methods
A PubMed and Scopus search was performed for articles using
combinations of the search terms: ‘‘Clostridium difﬁcile’’, ‘‘BI/NAP1/
027’’, ‘‘risk factors OR predictors’’, ‘‘outbreak’’, and ‘‘epidemic
strain’’. A time limit after the year 2000 was set. References of the
selected articles as well as references of relevant review articles
were also searched. We did not look for studies presented as
abstracts at conferences.
2.1. Study selection
Studies were eligible for inclusion in the meta-analysis if
they sought to recognize risk factors for CDI caused by theses. Published by Elsevier Ltd. All rights reserved.
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included; patients with CDI due to other strains or patients
with non-CDI with or without diarrhea could be included as the
control group. Studies that did not conﬁrm the ribotype of all
isolates were excluded.
2.2. Data extraction
Two authors (GL and AK) independently searched for and
extracted data on the methodology of each study, the hospital
setting, the primary scope of the study, age, sex, history of cases and
controls (including cardiovascular, pulmonary, chronic kidney, and
gastrointestinal disease, malignancy, and immunosuppression),
previous antibiotic therapy (including penicillins, aminoglycosides,
cephalosporins, ﬂuoroquinolones, macrolides, carbapenems, tetra-
cyclines, glycopeptides, and metronidazole) or other medications
(proton-pump inhibitors (PPIs), H2 blockers, inhibitors of angioten-
sin-converting enzyme, and statins), interventions (nasogastric
tubes, mechanical ventilation, endoscopy, and surgery), previous
hospitalization, nursing home residency, and intensive care unit
(ICU) stay. The risk factors identiﬁed in univariate and multivariate
analysis in each study were also collected.
2.3. Statistical analysis
Pooled odds ratios (OR) and 95% conﬁdence intervals (CI) were
calculated regarding all outcomes. Statistical heterogeneity
between studies was assessed using a Chi-square test (p < 0.10
was deﬁned to indicate signiﬁcant heterogeneity) and I2. The
Mantel–Haenszel random effects model (REM) was used for all
comparisons. The meta-analysis was performed with Review
Manager for Windows, version 5.1.
3. Results
The selection process is depicted in Figure 1. We identiﬁed
seven studies eligible for the analysis.8–14 The main characteristics
of the studies and the risk factors identiﬁed in each of them are
presented in Table 1. Overall ﬁve retrospective and two prospec-
tive studies were selected. Six studies were performed in Europe
and one in Canada.
Five studies compared CDI BI/NAP1/027 patients to patients
with CDI due to non-BI/NAP1/027 strains,8,10–13 one compared CDI
BI/NAP1/027 patients to non-CDI patients,9 and one provided dataStudies  inclu ded in  the syst ematic  re view 
Relevant articles  identifie d in Pu bMed  (n 
and Scopus (n = 309)  
Article s ass ess ed for eligibility  after  scree 
title and  abstra ct (n = 56 )
5 com pare d CDI-027  vs.  non-027 patients    1 com pare d CDI-027 , non-0 
Figure 1. Flow diagram for the selectiofor both comparisons.14 Six of them sought to identify risk factors
for the development of CDI BI/NAP1/027;9–14 three reported that
the risk factors independently associated with CDI BI/NAP1/027
were ﬂuoroquinolones,9,11,12 age over 65 years,9,11 hematological
malignancy,11 duration of hospitalization,9 use of nasogastric
tubes,9 use of any antibiotic including cephalosporins,9 and
combination of cephalosporins with ﬂuoroquinolones.9 The
resistance patterns of the isolated strains in the included studies
are shown in Table 2.
A meta-analysis using data from the included studies was
attempted in order to explore the heterogeneity of the reported risk
factors. Data were available for eight (age, sex, gastrointestinal
disease, malignancy, ﬂuoroquinolones, cephalosporins, macrolides,
and clindamycin) out of the 30 variables that we sought to collect.
Prior use of ﬂuoroquinolones was associated with a signiﬁcantly
higher risk of CDI due to BI/NAP1/027 when compared to non-BI/
NAP1/027 CDI (OR 1.96, 95% CI 1.37–2.80) but not to non-CDI
controls (OR 4.51, 95% CI 0.79–25.75; Figure 2). A trend towards a
lower risk of CDI due to BI/NAP1/027 was observed with
cephalosporins when compared to non-BI/NAP1/027 CDI (OR
0.70, 95% CI 0.46–1.07; Figure 3), while no higher risk of CDI due
to BI/NAP1/027 was observed with prior cephalosporin administra-
tion when compared to non-CDI controls (OR 3.19, 95% CI 0.64–
15.97). Prior macrolide administration did not increase the risk for
CDI BI/NAP1/027 when compared with non-BI/NAP1/027 CDI (OR
0.88, 95% CI 0.44–1.78; Figure 4), while the administration of
macrolides showed a trend towards an increased risk for CDI BI/
NAP1/027 when compared with non-CDI controls (OR 2.91, 95% CI
0.89–9.48). Clindamycin administration was associated with a lower
risk of CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027
CDI controls (OR 0.24, 95% CI 0.12–0.48; Figure 5); data for controls
without CDI were limited. Age over 65 years was associated with an
increased risk of CDI BI/NAP1/027 compared to non-BI/NAP1/027
CDI (OR 1.77, 95% CI 1.31–2.38), while gastrointestinal tract disease
(OR 1.23, 95% CI 0.74–2.04) and malignancy (OR 1.29, 95% CI 0.77–
2.18) were not associated with CDI due to BI/NAP1/027.
4. Discussion
The present meta-analysis sought to identify risk factors for CDI
BI/NAP1/027 compared to non-BI/NAP1/027 CDI and to non-CDI
controls. Three of the included studies concluded that independent
risk factors for the development of CDI BI/NAP1/027 were prior use (n = 7)  
= 285 ) 
ning of 
Articles exclude d (n = 49)  
• Epidemiological  studies  pr ovidi ng no  data  on  risk 
factors for CDI  027 (n = 17 ) 
• Molecular  or microbiological  st udies  (n = 7) 
• Case  or  cluster  report (n = 11) 
• Studies  focusin g on  the se verit y of  the  disease  (n = 9) 
• Studies  focusin g on  treatment  (n = 1) 
• Studie s di d not  speci fy strai ns in al l ca ses (n = 2)  
• Risk  factors  for  CDI at  hospital  level  (n = 2) 
1 com par ed CDI-027  vs . non-CDI  patie nts27 and  non-CDI  patients
n process of the included studies.
Table 1
Characteristics and outcomes of the included studies
First author, year of
publication (reference)
Design of the study Scope of the study Setting Populations, number of patients
with CDI-027/other
Risk factors for CDI-027 in multivariate
analysis
Debast et al., 20099 Retrospective case–control
study
Risk factors for CDI-027 SC in Europe (April–September 2005) CDI-027 vs. non-CDI, 45/90 1. Age above 65 years, p < 0.05
2. Duration of hospitalization p < 0.05
3. Antibiotic use
a. Any antibiotic p < 0.001
b. Cephalosporins p < 0.001
c. Fluoroquinolones p < 0.01
4. Antibiotic monotherapy in the
preceding 3 months p < 0.001
5. Combination of a cephalosporin and
a ﬂuoroquinolone p < 0.01
6. Nasogastric tube feeding p < 0.05
Sundram et al., 200914 Retrospective case–control
study
Risk factors for CDI-027
and non-027
SC in Europe (March 2006–March 2007) CDI-027 vs. CDI non-027 vs.
non-CDI, 44/81
NR
Labbe et al., 200813 Retrospective case–control
study
Risk factors for CDI-027 vs.
other types, susceptibility
SC in Canada (1999–2002) CDI-027 vs. CDI non-027/001,
141/89
NR
Goorhuis et al., 200712 Retrospective surveillance
study
Risk factors for CDI-027 vs.
other types
MC in Europe (February 2005–November 2006) CDI-027 vs. CDI other strains,
178/519
Fluoroquinolones
Fenner et al., 200810 Prospective case–control
study
Risk factors, phenotypic
and genotypic characteristics
of CDI-027
SC in Europe (2006–2007) CDI-027 vs. CDI other strains, 1
6/44
NR
Goorhuis et al., 201111 Retrospective case–control
study
Risk factors for CDI-027 vs.
other types
SC in Europe (May 2005–January 2007) CDI-027 vs. CDI non-027/017,
46/65
1. Ciproﬂoxacin DDD 3
2. Older age (65–80 years)
3. Hematological malignancy
Barbut et al., 20078 Prospective survey Describe the epidemiology
of CDI in Europe
MC Europe (April–June 2005) CDI-027 vs. CDI other, 20/302
patients
NR
CDI, Clostridium difﬁcile infection; CDI-027, Clostridium difﬁcile infection from 027 strain; DDD, deﬁned daily dose; MC, multicenter study; NR, not reported; SC, single center study.
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Table 2
Resistance to the tested antibiotics in the included studies
First author, year of
publication
Classes of antibiotics MIC50 of 027
strains (mg/l)
MIC90 of 027
strains (mg/l)
Characterization
of the strains
Frequency
of resistance
Debast et al., 20099 Erythromycin >256 - Resistant -
Ciproﬂoxacin >32 - Resistant -
Clindamycin 2 - Susceptible -
Metronidazole 0.19 - Susceptible -
Sundram et al., 200914 Cefotaxime 32 32 Resistant 95%
Ciproﬂoxacin 32 32 Resistant 95%
Erythromycin 256 256 Resistant 90%
Metronidazole 0.12 0.5 Susceptible 0%
Vancomycin (n = 43) 0.38 2 Susceptible 2%
Vancomycin (n = 1) 6 - Resistant 100%
Labbe et al., 200813 Ciproﬂoxacin >128 >128 Resistant -
Gatiﬂoxacin >32 >32 Resistant -
Clindamycin 4 8 Susceptible -
Metronidazole 1 1 Susceptible -
Vancomycin 0.5 2 Susceptible -
Azithromycin - - Resistant -
Goorhuis et al., 200712 Erythromycin >256 - Resistant 100%
Ciproﬂoxacin 32 - Resistant 100%
Moxiﬂoxacin 32 - Resistant 100%
Clindamycin 2 - Susceptible -
Metronidazole 0.19 - Susceptible -
Vancomycin 0.38 - Susceptible -
Fenner et al., 200810 Moxiﬂoxacin 32 - Resistant 100%
Metronidazole 0.064 0.25 Sensitive -
Vancomycin 0.25 1.5 Sensitive -
Goorhuis et al., 201111 Ciproﬂoxacin >32 - Resistant 100%
Erythromycin (n = 18) >256 - Resistant 94.7%
Clindamycin 4 - Susceptible -
Moxiﬂoxacin - - Resistant 89.4%
Barbut et al., 20078 Erythromycin 256 - Resistant 100%
Clindamycin 0.25–6 - Resistant 20%
Moxiﬂoxacin (n = 19) >12 - Resistant 100%
Moxiﬂoxacin (n = 1) 6 - Resistant 100%
Vancomycin 2 - Susceptible -
Metronidazole <0.50 - Susceptible -
MIC, minimum inhibitory concentration.
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duration of hospitalization, use of nasogastric tubes, and use of any
antibiotic. In addition, this meta-analysis found that prior
clindamycin administration was associated with a higher risk
for the development of CDI due to non-BI/NAP1/027 strains, while
prior macrolide or cephalosporin administration did not increase
the risk for CDI due to speciﬁc strains. Furthermore, it conﬁrmedFigure 2. Forest plot depicting the odds ratios (OR) for the risk of development of CDI du
difference’ point between the two regimens; squares = odds ratios; diamonds = pooledthat prior ﬂuoroquinolone administration and age over 65 years
were associated with a higher risk of CDI due to BI/NAP1/027 than
CDI due to other strains and non-CDI controls.
The selection of BI/NAP1/027 strains after the use of ﬂuor-
oquinolones can be explained by several assumptions. First, it
could be associated with the change in susceptibility of the normal
intestinal ﬂora to various antibiotics (colonization resistance).15e to 027 strain according to prior ﬂuoroquinolone administration (vertical line = ‘no
 odds ratios for all studies; horizontal lines = 95% conﬁdence interval).
Figure 3. Forest plot depicting the odds ratios (OR) for the risk of development of CDI due to 027 strain according to prior cephalosporin administration (vertical line = ‘no
difference’ point between the two regimens; squares = odds ratios; diamonds = pooled odds ratios for all studies; horizontal lines = 95% conﬁdence interval).
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to ﬂuoroquinolones, it has been documented that recently isolated
strains have become resistant to ﬂuoroquinolones.16 However,
ﬂuoroquinolone resistance has also been reported in other C.
difﬁcile strains. Third, the improved anti-anaerobe activity of
newer ﬂuoroquinolones has also been implicated. Fourth, animal
models have shown that the overgrowth of ﬂuoroquinolone-
resistant strains and the inhibition of ﬂuoroquinolone-sensitive
strains are supported by ﬂuoroquinolone administration.17 In
contrast, clindamycin was found to be associated with the
development of CDI due to non-BI/NAP1/027 strains. C. difﬁcile
BI/NAP1/027 strains isolated in most of the included studies were
sensitive to clindamycin, which might have eradicated these
strains and enabled the development of CDI due to non-BI/NAP1/
027 strains, as was the case with most non-BI/NAP1/027 strains
isolated in the included studies. Finally, other factors including
spore formation and colonization pressure, which could be
modiﬁed by antibiotic use but could not be tested in the included
studies, cannot be ruled out.11
An interesting observation was that six out of seven
included studies were conducted in Europe, where the
epidemic is less prominent than in the USA and Canada.Figure 4. Forest plot depicting the odds ratios (OR) for the risk of development of CDI 
difference’ point between the two regimens; squares = odds ratios; diamonds = pooledHowever, due to the strict criteria for inclusion we decided to
exclude two studies that were performed in America and
included patients with CDI predominantly due to the BI/NAP1/
027 strain.4,18 These studies were excluded because they did
not provide speciﬁc data regarding patients with BI/NAP1/027
strains and controls, or because not all strains could be
classiﬁed into speciﬁc ribotypes. Fluoroquinolones, cephalos-
porins, and proton pump inhibitors were found to be associated
with CDI due to the predominantly isolated BI/NAP1/027 strain
in these studies.
The present study has certain limitations. Only seven studies
could be included in the meta-analysis, and for the majority of
comparisons data from three or four studies were available.
Although some might argue that this is a small number for a meta-
analysis to produce meaningful comparisons, the available data did
provide clinically important ﬁndings. In addition, although the
scope of six of the included studies was to identify risk factors for
CDI due to the BI/NAP1/027 strain, only three ﬁnally provided data
from multivariate analyses. Finally, the available data did not allow
for a comparison of deﬁned daily dose (DDD) of the antibiotics, and
therefore the additional difference between ‘small’ and ‘large’
dosages could not be assessed.due to 027 strain according to prior macrolide administration (vertical line = ‘no
 odds ratios for all studies; horizontal lines = 95% conﬁdence interval).
Figure 5. Forest plot depicting the odds ratios (OR) for the risk of development of CDI due to 027 strain according to prior clindamycin administration (vertical line = ‘no
difference’ point between the two regimens; squares = odds ratios; diamonds = pooled odds ratios for all studies; horizontal lines = 95% conﬁdence interval).
K.Z. Vardakas et al. / International Journal of Infectious Diseases 16 (2012) e768–e773 e773In conclusion, the limited available data suggest that ﬂuor-
oquinolones and increasing age are the factors associated with CDI
BI/NAP1/027 when compared to other strains, while clindamycin
appears to be associated with a higher risk for CDI due to non-BI/
NAP1/027 strains. The role of other antimicrobials on the potential
selection of speciﬁc C. difﬁcile strains should be further studied.
Conﬂict of interest: We declare that we have no conﬂicts of
interest.
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